Last reviewed · How we verify
NCT05730660
Quercetin Phytosome® Chronic Fatigue Symptoms
NA trial testing Quercetin group in Chronic Fatigue Symptoms in 80 participants. Completed in 31 January 2023.
31 December 2022
Quick facts
| Lead sponsor | Azienda di Servizi alla Persona di Pavia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 September 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 January 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Quercetin group
- Placebo group
Conditions studied
- Chronic Fatigue Symptoms — all drugs for Chronic Fatigue Symptoms →
- Sleep — all drugs for Sleep →
- Physical Performance — all drugs for Physical Performance →
- Body Composition — all drugs for Body Composition →
Sponsor
Azienda di Servizi alla Persona di Pavia — full company profile →
Who can join
18 and older, any sex, with Chronic Fatigue Symptoms or Sleep. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate whether a 3-month period of quercetin supplementation (500 mg of Quercetin Phytosome®) is useful in the treatment of chronic fatigue, as assessed by the Fatigue Impact Scale (FIS-40). Secondary end points are sleep assessment through Pittsburgh Sleep Quality Index (PSQI) and muscle performance assessment through the Short Physical Performance Battery (SPPB) and body composition assessment using DXA.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic Potential of Quercetin as an Antioxidant for Bone-Muscle-Tendon Regeneration and Aging.
Kim JG, Sharma AR, Lee YH, Chatterjee S, et al · · 2024 · cited 21× · PMID 39012676 · DOI 10.14336/ad.2024.0282 -
Phytosomes against melanoma: disrupting molecular pathways with targeted phytochemical delivery.
Uniyal P, Bhardwaj N, Raina D. · · 2026 · PMID 42149379 · DOI 10.1186/s11671-026-04647-x
Verify or expand the search:
- PubMed search for NCT05730660
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Azienda di Servizi alla Persona di Pavia trials
Trials by the same sponsor.
- NCT07377409 — Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Ne · NA · not yet recruiting
- NCT06954038 — Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood · NA · not yet recruiting
- NCT06955234 — Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose · NA · not yet recruiting
- NCT06942897 — Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cor · NA · not yet recruiting
- NCT05730985 — From the Gut to the Strut: Reducing Inflammation for Healthy Muscles · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05730660 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda di Servizi alla Persona di Pavia
- Last refreshed: 6 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05730660.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing